Avidin fusion protein-expressing lentiviral vector for targeted drug delivery

Human Gene Therapy

Volumn 20, Issue 8, 2009, Pages 871-882

  Lesch, Hanna P ^a,b   Pikkarainen, Jere T ^a,b   Kaikkonen, Minna U ^a,b   Taavitsainen, Miia ^a,b   Samaranayake, Haritha ^a,b   Lehtolainen Dalkilic, Pauliina ^b   Vuorio, Taina ^a,b   Määttä, Ann Marie ^b   Wirth, Thomas ^a   Airenne, Kari J ^a   Ylä Herttuala, Seppo ^a,c  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b Finland Ark Therapeutics Oy   (Finland)

^c KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AVIDIN; BIOTIN; LENTIVIRUS VECTOR; NANOPARTICLE; PACLITAXEL; VIRUS FUSION PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TARGETING; HUMAN; HUMAN CELL; LIGAND BINDING; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS PARTICLE;

ANIMALS; ANTIBODIES; ANTIBODY FORMATION; AVIDIN; BIOTIN; CELL MEMBRANE; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; GENETIC VECTORS; HELA CELLS; HUMANS; LENTIVIRUS; NEUTRALIZATION TESTS; RATS; RECOMBINANT FUSION PROTEINS; SERUM; TRANSDUCTION, GENETIC; VIRION;

LENTIVIRUS; RATTUS;

EID: 68949221588     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.007     Document Type: Article

References (35)

1. Axworthy, D.B., Reno, J.M., Hylarides, M.D., Mallett, R.W., Theodore, L.J., Gustavson, L.M., Su, F., Hobson, L.J., Beaumier, P.L., and Fritzberg, A.R. (2000). Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. U.S.A. 97, 1802-1807.
2. Baekelandt, V., Claeys, A., Eggermont, K., Lauwers, E., De, S.B., Nuttin, B., and Debyser, Z. (2002). Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. Hum. Gene Ther. 13, 841-853.
3. Baekelandt, V., Eggermont, K., Michiels, M., Nuttin, B., and Debyser, Z. (2003). Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain. Gene Ther. 10, 1933-1940.
4. Bessis, N., GarciaCozar, F.J., and Boissier, M.C. (2004). Immune responses to gene therapy vectors: Influence on vector function and effector mechanisms. Gene Ther. 11(Suppl. 1), S10-S17.
5. Cronin, J., Zhang, X.Y., and Reiser, J. (2005). Altering the tropism of lentiviral vectors through pseudotyping. Curr. Gene Ther. 5, 387-398.
6. DePolo, N.J., Reed, J.D., Sheridan, P.L., Townsend, K., Sauter, S.L., Jolly, D.J., and Dubensky, T.W., Jr. (2000). VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol. Ther. 2, 218-222.
7. Farson, D., Witt, R., McGuinness, R., Dull, T., Kelly, M., Song, J., Radeke, R., Bukovsky, A., Consiglio, A., and Naldini, L. (2001). A new-generation stable inducible packaging cell line for lentiviral vectors. Hum. Gene Ther. 12, 981-997.
8. Follenzi, A., and Naldini, L. (2002). Generation of HIV-1 derived lentiviral vectors. Methods Enzymol. 346, 454-465.
9. Follenzi, A., Santambrogio, L., and Annoni, A. (2007). Immune responses to lentiviral vectors. Curr. Gene Ther. 7, 306-315.
10. Frolov, I., Hoffman, T.A., Pragai, B.M., Dryga, S.A., Huang, H.V., Schlesinger, S., and Rice, C.M. (1996). Alphavirus-based expression vectors: strategies and applications. Proc. Natl. Acad. Sci. U.S.A. 93, 11371-11377.
11. Geraerts, M., Willems, S., Baekelandt, V., Debyser, Z., and Gijsbers, R. (2006). Comparison of lentiviral vector titration methods. BMC Biotechnol. 6, 34.
12. Goodwin, D.A., and Meares, C.F. (2001). Advances in pretargeting biotechnology. Biotechnol. Adv. 19, 435-450.
13. Grana, C., Chinol, M., Robertson, C., Mazzetta, C., Bartolomei, M., De, C.C., Fiorenza, M., Gatti, M., Caliceti, P., and Paganelli, G. (2002). Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: A pilot study. Br. J. Cancer 86, 207-212.
14. Green, N.M. (1990). Avidin and streptavidin. Methods Enzymol. 184, 51-67.
15. + cells with HIV-1-derived lentiviral vectors. Mol. Ther. 2, 71-80.
16. Hao, M., and Maxfield, F.R. (2000). Characterization of rapid membrane internalization and recycling. J. Biol. Chem. 275, 15279-15286.
17. Hytonen, V.P., Laitinen, O.H., Grapputo, A., Kettunen, A., Savolainen, J., Kalkkinen, N., Marttila, A.T., Nordlund, H.R., Nyholm, T.K., Paganelli, G., and Kulomaa, M.S. (2003). Characterization of poultry egg-white avidins and their potential as a tool in pretargeting cancer treatment. Biochem. J. 372, 219-225.
18. King, G.D., Kroeger, K.M., Bresee, C.J., Candolfi, M., Liu, C., Manalo, C.M., Muhammad, A.K., Pechnick, R.N., Lowenstein, P.R., and Castro, M.G. (2008). Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Mol. Ther. 16, 682-690.
19. Lehtolainen, P., Wirth, T., Taskinen, A.K., Lehenkari, P., Leppanen, O., Lappalainen, M., Pulkkanen, K., Marttila, A., Marjomaki, V., Airenne, K.J., Horton, M., Kulomaa, M.S., and Ylä-Herttuala, S. (2003). Targeting of biotinylated compounds to its target tissue using a low-density lipoprotein receptor-avidin fusion protein. Gene Ther. 10, 2090-2097.
20. Liu, H.S., Jan, M.S., Chou, C.K., Chen, P.H., and Ke, N.J. (1999). Is green fluorescent protein toxic to the living cells? Biochem. Biophys. Res. Commun. 260, 712-717.
21. Logan, A.C., Nightingale, S.J., Haas, D.L., Cho, G.J., Pepper, K.A., and Kohn, D.B. (2004). Factors influencing the titer and infectivity of lentiviral vectors. Hum. Gene Ther. 15, 976-988.
22. Nash, K.L., and Lever, A.M. (2004). Green fluorescent protein: Green cells do not always indicate gene expression. Gene Ther. 11, 882-883.
23. Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F.H., Verma, I.M., and Trono, D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267.
24. Paganelli, G., Stella, M., De, N.P., Magnani, P., Zito, F., Siccardi, A.G., Di Carlo, V, and Fazio, F. (1991). A new method for faster blood clearance in radioimmuno-guided surgery. J. Nucl. Biol. Med. 35, 88-89.
25. Park, F., Ohashi, K., and Kay, M.A. (2000). Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood 96, 1173-1176.
26. Pulkkinen, M., Pikkarainen, J., Wirth, T., Tarvainen, T., Haapaaho, V., Korhonen, H., Seppala, J., and Jarvinen, K. (2008). Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity. Eur. J. Pharm. Biopharm. 70, 66-74.
27. Raty, J.K., Lesch, H.P., Wirth, T., and Ylä-Herttuala, S. (2008). Improving safety of gene therapy. Curr. Drug Saf. 3, 46-53.
28. Rheme, C., Ehrengruber, M.U., and Grandgirard, D. (2005). Alphaviral cytotoxicity and its implication in vector development. Exp. Physiol. 90, 45-52.
29. Rodrigues, T., Carrondo, M.J., Alves, P.M., and Cruz, P.E. (2007). Purification of retroviral vectors for clinical application: Biological implications and technological challenges. J. Biotechnol. 127, 520-541.
30. Sastry, L., Johnson, T., Hobson, M.J., Smucker, B., and Cornetta, K. (2002). Titering lentiviral vectors: Comparison of DNA,RNA and marker expression methods. Gene Ther. 9, 1155-1162.
31. Sastry, L., Xu, Y., Johnson, T., Desai, K., Rissing, D., Marsh, J., and Cornetta, K. (2003). Certification assays for HIV-1-based vectors: Frequent passage of gag sequences without evidence of replication-competent viruses. Mol. Ther. 8, 830-839.
32. Schauber-Plewa, C., Simmons, A., Tuerk, M.J., Pacheco, C.D., and Veres, G. (2005). Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation. Gene Ther. 12, 238-245.
33. Tyynela, K., Sandmair, A.M., Turunen, M., Vanninen, R., Vainio, P., Kauppinen, R., Johansson, R., Vapalahti, M., and Ylä-Herttuala, S. (2002). Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model. Cancer Gene Ther. 9, 917-924.
34. Watson, D.J., Kobinger, G.P., Passini, M.A., Wilson, J.M., and Wolfe, J.H. (2002). Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol. Ther. 5, 528-537.
35. Zempleni, J. (2005). Uptake, localization, and noncarboxylase roles of biotin. Annu. Rev. Nutr. 25, 175-196.